Exelixis (NASDAQ: EXEL) is not the most popular drugmaker around, but there are several noteworthy things about this mid-cap stock. First, it is laser focused on just one area, oncology, which is the largest and one of the fastest-growing therapeutic areas in the industry.
Second, Exelixis has had tremendous success in recent years through just one product, Cabometyx, a cancer drug that has earned plenty of approvals and continues to do so. Even so, some investors may be turned off by the company's reliance on Cabometyx.
Despite this issue, there are solid reasons to bet on Exelixis. Let's consider why the company's shares are worth considering right now.
Source Fool.com